Product Details

PROIN ER is the only FDA-approved once-daily medication for the control of canine urinary incontinence (UI) due too urethral sphincter hypotonus.

Indication
PROIN ER is indicated for the control of urinary incontinence due to urethral sphincter hypotonus in dogs.

Available as	For use with	Strengths
Tablet	Canines	18, 38, 74 or 145 mg tablet

A First-Line UI Treatment Per ACVIM Consensus^¹

PROIN ER is indicated for the control of canine UI due to urethral sphincter hypotonus.

Treatment Compliance

Simple once-daily dosing helps clients adhere to treatment, which can improve patient outcomes.^¹

Cost-Effective

Lower cost of treatment can make quality care more accessible and offer long-term affordability for pet owners.

Consistent Control

Patented extended-release technology provides controlled delivery that ensures steady absorption, reducing the occurrence of UI episodes.

Broad Tolerability

Formulated with hydrolyzed protein, making it an alternative for dogs with dietary sensitivities.*

Precautions

PROIN ER may cause hypertension; therefore, use with caution in dogs with pre-existing heart disease, hypertension, liver disease, kidney insufficiency, diabetes, glaucoma, and conditions with a predilection for hypertension.

Use caution in dogs receiving sympathomimetic drugs, tricyclic antidepressants, or monoamine oxidase inhibitors as increased toxicity may result. Use with caution in dogs administered halogenated gaseous anesthetics as this may increase the risk of cardiac arrhythmias.

About PROIN ER

About Canine UI

Urethral Sphincter Mechanism Incompetence
Urethral sphincter mechanism incompetence (USMI) is the most common cause of urinary incontinence in dogs affecting up to 20% of neutered female dogs and 30% of those over 44 lbs. It is less commonly reported in neutered males and intact dogs of both sexes. In most dogs it occurs within 3 years of neutering, although in many it may not become a major problem until later in life when it can be complicated by diseases that cause polyuria and polydipsia.1,10

Canine UI Patient Profile

Predisposed Breeds
Large dogs are more likely to develop UI due to urethral sphincter hypotonus. Among the most common breeds affected are the Old English sheepdog, Doberman pinscher, Boxer, German Shepherd Dog, and Weimeraner.10 A recent study indicates that earlier spaying/neutering  may increase the risk of development of urinary sphincter mechanism incompetence in dogs with a projected adult body weight greater  than 33 lbs.10
The Impact of Canine UI

Inappropriate urination due to urethral sphincter hypotonus most commonly happens when a dog is sleeping or relaxing, meaning that the comfy places they love most (couches, beds, carpets) become off limits.

74% of dog owners indicate “leaking” would impact sharing space with their dog.^²

68% of dog owners indicate “leaking” would affect decisions about whether to include their dog in personal activities.^²

PROIN ER Detailer

Educate your team about canine UI and PROIN ER.

Download the PROIN ER Detailer

PROIN ER Pet Owner Brochure

Teach your clients about UI and how PROIN ER can help.

Download the PROIN ER Pet Owner Brochure

References

^¹Kendall A, Byron JK, Westropp JL, Coates JR, Vaden S, Adin C, Oetelaar G, Bartges JW, Foster JD, Adams LG, Olby N, Berent A. ACVIM consensus statement on diagnosis and management of   urinary incontinence in dogs. J Vet Intern Med. 2024 Mar-Apr;38(2):878-903. doi: 10.1111/jvim.16975. Epub 2024 Jan 13. PMID: 38217372; PMCID: PMC10937496.

^²Barter LS et al. 2015; Adams VJ et al. J Small Anim Pract. 2005.

^³Richter K.P., Ling G.V. Clinical response and urethral pressure profile changes after phenylpropanolamine in dogs with primary sphincter incompetence. JAVMA, Vol. 187, No 6, September 15,   1985. 605-611.

^⁴Scott, L., Leddy M. and Bernay, F. Evaluation of phenylpropanolamine in the treatment of urethral sphincter mechanism incompetence in the bitch. J. Small Anim. Pract. 2002;43(11): 493-6.

^⁵Noel, S., et al. Combined pharmacokinetic and urodynamic study of the effects of oral administration of phenylpropanolamine in female Beagle dogs. Vet. Journal, 2010; 184(2): 201-207.

^⁶Pegasus Laboratories, Inc. (2019). Freedom of Information (FOI) Summary for PROIN ER (phenylpropanolamine hydrochloride extended-release tablets) Dogs: U.S., (NADA 141-517). Center   for Veterinary Medicine (CVM).

^⁷Kynetec 2022 Urinary Incontinence in Canine Survey.

^⁸Consumer Dog Owner survey conducted by PRN Pharmacal, December 2022.

^⁹FDA-CVM FOI Summary, PROIN ER, NADA 141-517 (March 29, 2019)

^¹⁰Byron JK, Taylor KH, Phillips GS, Stahl MS. Urethral Sphincter Mechanism Incompetence in 163 Neutered Female Dogs: Diagnosis, Treatment, and Relationship of Weight and Age at Neuter to Development of Disease. J Vet Intern Med 2017;31:442–448.

*While hydrolyzed proteins reduce the risk of immunologic reactivity, individual sensitivities may still occur.

Target Patient	Most common in middle-aged/older female dogs who’ve been spayed but can also occur in male dogs
Presentation	Leaks urine when sleeping or relaxed
Progression	Happens out of nowhere to house-trained dogs
Treatment	Can be treated with once-daily PROIN ER